From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement
News & Literature Highlights

BMS Press Release

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

JAMA

“Off-the-Shelf” CAR T-Cell Therapy Tested in Pediatric B-Cell Leukemia

Blood (2022 ASH Abstract)

Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies—Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113.

Blood (2022 ASH Abstract)

Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site.

Blood (2022 ASH Abstract)

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Blood

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Lancet Haematology

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study

Journal of Clinical Oncology

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.

Blood

Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy

Lancet Haematology

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Advertisement
Advertisement